Daiichi Sankyo Co. Ltd., of Tokyo, and Agendia BV, of Amsterdam, inked an oncology drug development and personalized medicine deal calling for Agendia's oncology biomarker technology to be used in the assessment of pharmaceuticals now being researched in certain Daiichi clinical trials. As part of the deal, Agendia's technology will be used to assess patient samples. Terms and other aspects of the agreement were not disclosed.
Janssen Biotech Inc., of Horsham, Pa., said the FDA approved Sylvant (siltuximab), an interleukin-6 antagonist administered as an intravenous infusion once every three weeks, for the treatment of patients with multicentric Castleman's disease (MCD) who are HIV-negative and human herpesvirus-8-negative. Sylvant is the first approved treatment in the U.S. for MCD, a rare blood disorder with high morbidity in which lymphocytes are overproduced, leading to enlarged lymph nodes. A recent U.S. analysis estimates the incidence of MCD to be about 1,100 to 1,300 patients.